Traders should monitor the March 31 earnings call for potential updates on clinical progress, cash runway, or funding needs, which could impact valuation given the company's pre-revenue status.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 24 $116.23entry
- T+1 · 8mo ago +3.58%α +3.01% · $120.39
- T+5 · 8mo ago +7.24%α +7.67% · $124.65
- T+20 · 7mo ago +12.40%α +3.50% · $130.64
- T+60 · 5mo ago −2.69%α −17.02% · $113.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Palvella Therapeutics announced it will report its full year 2025 financial results on March 31, 2026, followed by a conference call to discuss the results and provide a corporate update. The press release contains no actual financial data, only logistical details about the upcoming earnings announcement.
Key Facts
- Palvella Therapeutics will report full year 2025 financial results on March 31, 2026, before market open.
- Management will host a conference call at 8:30 a.m. ET on March 31, 2026, to discuss results and provide a corporate update.
- No financial results, guidance, or operational updates were disclosed in this release.
- Company remains in clinical-stage development with no FDA-approved therapies yet.
Financial Impact
No financial data disclosed in this release
Risk Factors
- No revenue-generating products; dependent on clinical trial outcomes and future financing.
- Failure to meet clinical or regulatory milestones could negatively impact stock price.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261100 |
Track record
36 reports on PVLA
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
- Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
- Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
- Nov 5, 202611d ago Press Release Neutral 6/10 No price data
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
- Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers